Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
HOCH Abgang Schlüsselpersonen (09.03.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 09.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ecific reference in such a filing. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointm |
| 15.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 12.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 17.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 27.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | xchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certa |
| 25.05.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce |
Stammdaten
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Unternehmen & Branche
| Name | SPRUCE BIOSCIENCES, INC. |
|---|---|
| Ticker | SPRB |
| CIK | 0001683553 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 74,7 Mio. USD |
| Beta | 3,68 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 0 | -38,966,000 | -50.83 | 53,021,000 | 42,516,000 |
| 2025-09-30 | 10-Q | 0 | -8,212,000 | -14.58 | 15,313,000 | 5,386,000 |
| 2025-06-30 | 10-Q | 0 | -2,067,000 | -3.50 | 21,820,000 | 13,180,000 |
| 2025-03-31 | 10-Q | 0 | -14,041,000 | -0.32 | 31,649,000 | 15,324,000 |
| 2024-12-31 | 10-K | 4,911,000 | -53,036,000 | -96.40 | 45,209,000 | 28,821,000 |
| 2024-09-30 | 10-Q | 602,000 | -8,671,000 | -15.75 | 65,102,000 | 51,638,000 |
| 2024-06-30 | 10-Q | 1,610,000 | -9,181,000 | -16.73 | 75,519,000 | 59,169,000 |
| 2024-03-31 | 10-Q | 2,002,000 | -11,625,000 | -0.28 | 87,539,000 | 66,624,000 |
| 2023-12-31 | 10-K | 10,089,000 | -47,919,000 | -1.24 | 103,946,000 | 76,509,000 |
| 2023-09-30 | 10-Q | 3,073,000 | -12,354,000 | -0.30 | 112,985,000 | 85,381,000 |
| 2023-06-30 | 10-Q | 2,165,000 | -12,824,000 | -0.32 | 125,962,000 | 96,561,000 |
| 2023-03-31 | 10-Q | 1,964,000 | -12,791,000 | -0.40 | 139,114,000 | 107,997,000 |
| 2022-12-31 | 10-K | 0 | -46,180,000 | -1.96 | 85,648,000 | 68,486,000 |
| 2022-09-30 | 10-Q | 0 | -11,401,000 | -0.48 | 95,298,000 | 78,475,000 |
| 2022-06-30 | 10-Q | 0 | -11,872,000 | -0.51 | 104,515,000 | 89,121,000 |
| 2022-03-31 | 10-Q | 0 | -11,762,000 | -0.50 | 114,988,000 | 100,243,000 |
| 2021-12-31 | 10-K | -42,292,000 | -1.81 | 126,486,000 | 111,371,000 | |
| 2021-09-30 | 10-Q | -11,447,000 | -0.49 | 135,087,000 | 119,720,000 | |
| 2021-06-30 | 10-Q | -11,774,000 | 143,448,000 | 130,106,000 | ||
| 2021-03-31 | 10-Q | -9,887,000 | 153,991,000 | 140,723,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-10-06 | Parkman Healthcare Partners LLC | 10% Owner | Open Market Purchase | 256 | 17.91 | 4,585.16 | +144,7% | |
| 2025-10-06 | Parkman Healthcare Partners LLC | 10% Owner | Open Market Sale | -25 | 17.46 | -436.39 | -13,8% | |
| 2025-10-06 | Parkman Healthcare Partners LLC | 10% Owner | Open Market Sale | -232 | 19.33 | -4,483.72 | -141,5% | |
| 2025-10-06 | Parkman Healthcare Partners LLC | 10% Owner | Open Market Purchase | 256 | 17.91 | 4,585.16 | +144,7% | |
| 2025-10-06 | Parkman Healthcare Partners LLC | 10% Owner | Open Market Sale | -25 | 17.46 | -436.39 | -13,8% | |
| 2025-10-06 | Parkman Healthcare Partners LLC | 10% Owner | Open Market Sale | -232 | 19.33 | -4,483.72 | -141,5% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.